-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
RO-7
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/1370241-45-4.gif)
| Category | Influenza Virus |
| CAS | 1370241-45-4 |
| Description | RO-7 is a next-generation polymerase (PA) endonuclease inhibitor of influenza A and B viruses. |
Product Information
| Synonyms | RO-7|1-[(11S)-6,11-dihydrodibenzo[b,e]thiepin-11-yl]-5-hydroxy-3-[(2R)-1,1,1-trifluoropropan-2-yl]-2,3-dihydro-1H-pyrido[2,1-f][1,2,4]triazine-4,6-dione|CHEMBL4103104|SCHEMBL10290465|BDBM346802|GLXC-15013|US10202379, Reference Example 413|HY-112684|CS-0062623|1-(5,11-Dihydro-10-thia-dibenzo[a,d]cyclohepten-5(S)-yl)-5-hydroxy-3-(2,2,2-trifluoro-1(R)-methyl-ethyl)-2,3-dihydro-1H-pyrido[2,1-f][1,2,4]triazine-4,6-dione|1370241-45-4|R07 |
| Molecular Weight | 487.49 |
| Molecular Formula | C24H20F3N3O3S |
| Canonical SMILES | CC(C(F)(F)F)N1CN(N2C=CC(=O)C(=C2C1=O)O)C3C4=CC=CC=C4CSC5=CC=CC=C35 |
| Purity | ≥98% (HPLC) |
| Solubility | In Vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 908 |
| Exact Mass | 487.11774717 |
| In Vitro | RO-7 is a compound that potently inhibits influenza virus replication and belongs to a new class of drugs in late-stage clinical trials for treatment of influenza virus infection. RO-7 displays broad-spectrum anti-influenza activity in vitro and protects mice from lethal challenge with both influenza A and B viruses. |
| In Vivo | RO-7 protects mice from lethal challenge with both influenza A and B viruses. |
| Target | Influenza Virus |
| XLogP3-AA | 5.3 |
